SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

NCT01075308 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: HDAC inhibitor SB939

Sponsor

NCIC Clinical Trials Group

Collaborators

[object Object]